Dehydrovomifoliol Alleviates Nonalcoholic Fatty Liver Disease via the E2F1/AKT/mTOR Axis: Pharmacophore Modeling and Molecular Docking Study

Figure 4

Molecular docking analysis of candidate proteins and dehydrovomifoliol using AutoDockTools 1.5.6 and Vina 1.5.6 software. (a) Molecular docking of E2F1 and dehydrovomifoliol. (b) Molecular docking of MERTK and dehydrovomifoliol. (c) Molecular docking of SOX17 and dehydrovomifoliol. (d) Molecular docking of MMP9 and dehydrovomifoliol. (e) Molecular docking of SULT2A1 and dehydrovomifoliol. (f) Molecular docking of VEGFA and dehydrovomifoliol. (g) Molecular docking of BLVRA and dehydrovomifoliol. (h) A bar graph of the affinity of E2F1, MERTK, SOX17, MMP9, SULT2A1, VEGFA, and BLVRA to dehydrovomifoliol. It was noted that E2F1 had the highest binding free energy to dehydrovomifoliol compared to the other protein molecules.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)